DavidWheeler United KingdomUniversity College London

David C WheelerrDavid is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinical scientist interested in chronic kidney disease (CKD). He has participated in the development and delivery of several large-scale clinical trials testing lipid lowering regimens (SHARP), calcimimetics (EVOLVE), intravenous iron (PIVOTAL), SGLT2 inhibitors (CREDENCE and DAPA-CKD) and HIF stabilisers (ASCEND) in patients with CKD. He was co-chief investigator for the DAPA-CKD study (with Hiddo Lambers Heerspink). David has been involved in the development of Clinical Practice Guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-chair between 2012 and 2019. Other recent roles include Chair of the International Society of Nephrology Advancing Clinical Trials (ISN-ACTs) committee. In the UK, he is National Institute of Health Research (NIHR) Specialty Lead for Renal Disorders.

First name

David

Upload Picture

https://storage.unitedwebnetwork.com/files/1099/4ebc6caaa51e79209f4061cd08dff279.jpg

Last name

Wheeler

Institution

Country

United Kingdom

Friday, February 7, 2025

Time	Session

14:15 15:45	Bridging the Clinical Gap: Sustainable Strategies and Innovative Therapies for Global Kidney Health BKH02 ErangaWijewickrama Chair Sri LankaFaculty of Medicine, University of Colombo Prof (Dr ) SanjeevGulati Chair sgulati2002@gmail.comIndiaExecutive Director Nephrology and Kidney Transplant, Fortis gp of Hospitals and Adjunct Professor, Manipal University Sustainable Community Approaches to Early CKD Detection BKH02-01 RonaldGansevoort Speaker NetherlandsDept. Nephrology, University Medical Center Groningen Kidney Disease Treatment Gaps Worldwide - Where Are the Solutions? BKH02-02 AdeeraLevin Speaker alevin@providencehealth.bc.caCanadaUniversity of British Columbia and Providence Health Care The Promise of Emerging Therapies in Reducing the Global Kidney Disease Burden BKH02-03 DavidWheeler Speaker d.wheeler@ucl.ac.ukUnited KingdomUniversity College London Co-opting Patients as Partners in Kidney Care: How Do We Do It? BKH02-04 ShilpanjaliJesudason Speaker shilpa.jesudason@sa.gov.auAustraliaRoyal Adelaide Hospital and Adelaide University, Australia Co-opting Patients as Partners in Kidney Care: How Do We Do It? BKH02-05 ShyamsundarMuthuramalingam Speaker Shyamsundar.Muthuramalingam@sa.gov.auAustraliaCentral Adelaide Local Health Network Q&A BKH02-06 Kesar Hall 202

Time

Session

14:15

15:45

Bridging the Clinical Gap: Sustainable Strategies and Innovative Therapies for Global Kidney Health

BKH02

ErangaWijewickrama Chair Sri LankaFaculty of Medicine, University of Colombo

Prof (Dr ) SanjeevGulati Chair sgulati2002@gmail.comIndiaExecutive Director Nephrology and Kidney Transplant, Fortis gp of Hospitals and Adjunct Professor, Manipal University

Sustainable Community Approaches to Early CKD Detection

BKH02-01

RonaldGansevoort Speaker NetherlandsDept. Nephrology, University Medical Center Groningen
Kidney Disease Treatment Gaps Worldwide - Where Are the Solutions?

BKH02-02

AdeeraLevin Speaker alevin@providencehealth.bc.caCanadaUniversity of British Columbia and Providence Health Care
The Promise of Emerging Therapies in Reducing the Global Kidney Disease Burden

BKH02-03

DavidWheeler Speaker d.wheeler@ucl.ac.ukUnited KingdomUniversity College London
Co-opting Patients as Partners in Kidney Care: How Do We Do It?

BKH02-04

ShilpanjaliJesudason Speaker shilpa.jesudason@sa.gov.auAustraliaRoyal Adelaide Hospital and Adelaide University, Australia
Co-opting Patients as Partners in Kidney Care: How Do We Do It?

BKH02-05

ShyamsundarMuthuramalingam Speaker Shyamsundar.Muthuramalingam@sa.gov.auAustraliaCentral Adelaide Local Health Network
Q&A

BKH02-06

Kesar Hall 202

Saturday, February 8, 2025

Time	Session

14:15 15:45	What’s Next in Kidney Care Research? Innovations and Clinical Trials on the Horizon SS2 AdeeraLevin Chair alevin@providencehealth.bc.caCanadaUniversity of British Columbia and Providence Health Care Andrea Viecelli Chair SwitzerlandUniversity Hospital of Zurich Ajit singhNarula Chair narulaas@gmail.comIndia Novel Trial Designs in Nephrology: Innovations and Structures SS2-01 MegJardine Speaker meg.jardine@sydney.edu.auAustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia What’s New in Clinical Trials? SS2-02 DavidWheeler Speaker d.wheeler@ucl.ac.ukUnited KingdomUniversity College London Value of Different Outcomes in the Era of Precision Medicine SS2-03 RobertoPecoits-Filho Speaker United StatesArbor Research Collaborative for Health Conducting Trials in Low and Middle-income Countries SS2-04 SoumitaBagchi Speaker soumita_bagchi@yahoo.co.inIndiaProfessor, Department of Nephrology, All India Institute of Medical Sciences, New Delhi Innovations in Pediatric Nephrology Discovery and Clinical Trial Conduct SS2-05 ArpanaIyengar Speaker arpanaiyengar@gmail.comIndiaST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES, BANGALORE Q&A SS2-06 Parijat Hall 201

Time

Session

14:15

15:45

What’s Next in Kidney Care Research? Innovations and Clinical Trials on the Horizon

SS2

AdeeraLevin Chair alevin@providencehealth.bc.caCanadaUniversity of British Columbia and Providence Health Care

Andrea Viecelli Chair SwitzerlandUniversity Hospital of Zurich

Ajit singhNarula Chair narulaas@gmail.comIndia

Novel Trial Designs in Nephrology: Innovations and Structures

SS2-01

MegJardine Speaker meg.jardine@sydney.edu.auAustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia
What’s New in Clinical Trials?

SS2-02

DavidWheeler Speaker d.wheeler@ucl.ac.ukUnited KingdomUniversity College London
Value of Different Outcomes in the Era of Precision Medicine

SS2-03

RobertoPecoits-Filho Speaker United StatesArbor Research Collaborative for Health
Conducting Trials in Low and Middle-income Countries

SS2-04

SoumitaBagchi Speaker soumita_bagchi@yahoo.co.inIndiaProfessor, Department of Nephrology, All India Institute of Medical Sciences, New Delhi
Innovations in Pediatric Nephrology Discovery and Clinical Trial Conduct

SS2-05

ArpanaIyengar Speaker arpanaiyengar@gmail.comIndiaST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES, BANGALORE
Q&A

SS2-06

Parijat Hall 201

Sunday, February 9, 2025

Time	Session

09:00 10:30	HIT! High Impact Clinical Trials – Why and How HIT2 DavidWheeler Chair d.wheeler@ucl.ac.ukUnited KingdomUniversity College London Winston Wing ShingFung Chair winstonwsfung@hotmail.comHong Kong, ChinaPrince of Wales Hospital, Hong Kong What Have We Learned From CONVINCE? HIT2-1 PeterBlankestijn Oral Abstract Presenter P.J.Blankestijn@umcutrecht.nlNetherlandsUniversity Medical Center Utrecht Design of the ZEUS Trial: Interleukin-6 Inhibition With Ziltivekimab for Cardiovascular Protection in Chronic Kidney Disease HIT2-2 VladoPerkovic Oral Abstract Presenter AustraliaUniversity of New South Wales, Sydney, Australia A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN) HIT2-3 Jonathan Barratt Oral Abstract Presenter jb81@leicester.ac.ukUnited KingdomUniversity of Leicester, Leicester, UK Observational Cohort With Embedded Randomized Controlled Trials to Study Pregnancy-Associated Progression of Renal Disease: A Feasibility Study of Dietary Nitrate (Beetroot Juice) to Protect Kidney Function in Pregnant Women With Chronic Kidney Disease HIT2-4 KateBramham Oral Abstract Presenter United KingdomKing's College London Design of Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary Glomerular Diseases: Multi-Center, Multi-Arm and Multi-Stage HIT2-5 Selvin Sundar RajMani Oral Abstract Presenter IndiaAssociate Professor in Nephrology, Christian Medical College, Vellore, India SuceenaAlexander Oral Abstract Presenter suceena@gmail.comIndiaChristian Medical College Vellore Brahmkamal Hall - Plenary Hall

Time

Session

09:00

10:30

HIT! High Impact Clinical Trials – Why and How

DavidWheeler Chair d.wheeler@ucl.ac.ukUnited KingdomUniversity College London

Winston Wing ShingFung Chair winstonwsfung@hotmail.comHong Kong, ChinaPrince of Wales Hospital, Hong Kong

What Have We Learned From CONVINCE?

HIT2-1

PeterBlankestijn Oral Abstract Presenter P.J.Blankestijn@umcutrecht.nlNetherlandsUniversity Medical Center Utrecht
Design of the ZEUS Trial: Interleukin-6 Inhibition With Ziltivekimab for Cardiovascular Protection in Chronic Kidney Disease

HIT2-2

VladoPerkovic Oral Abstract Presenter AustraliaUniversity of New South Wales, Sydney, Australia
A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)

HIT2-3

Jonathan Barratt Oral Abstract Presenter jb81@leicester.ac.ukUnited KingdomUniversity of Leicester, Leicester, UK
Observational Cohort With Embedded Randomized Controlled Trials to Study Pregnancy-Associated Progression of Renal Disease: A Feasibility Study of Dietary Nitrate (Beetroot Juice) to Protect Kidney Function in Pregnant Women With Chronic Kidney Disease

HIT2-4

KateBramham Oral Abstract Presenter United KingdomKing's College London
Design of Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary Glomerular Diseases: Multi-Center, Multi-Arm and Multi-Stage

HIT2-5

Selvin Sundar RajMani Oral Abstract Presenter IndiaAssociate Professor in Nephrology, Christian Medical College, Vellore, India

SuceenaAlexander Oral Abstract Presenter suceena@gmail.comIndiaChristian Medical College Vellore

Brahmkamal Hall - Plenary Hall